Latest Ibritumomab tiuxetan Stories

- Results Presented at 18th Congress of the European Hematology Association - SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from sub-set analyses of data from the Phase 3 EXTEND, or PIX301, clinical trial of PIXUVRI(®) (pixantrone). The analyses evaluated the efficacy of PIXUVRI in the subset of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), as confirmed by central independent...

Research compares standard treatment and addition of targeted therapy with radiolabeled antibodies that track and kill lymphoma cancer cells A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy (RIT) may become the most powerful cancer-killing therapy available, with the hope that patients’ lymphoma can be eradicated as they prepare for bone marrow transplant, say researchers at the 2013 Annual Meeting of the Society of...

Comprehensive dosimetry based on 3D medical images estimate best possible dose for targeted radioimmunotherapy (RIT) in patients with invasive blood cancer Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system. Accurate estimation of radiation absorbed dose in radioimmunotherapy (RIT) based on state-of-the-art 3D imaging could lead to more personalized and effective treatments to improve patients’ chances of living...

SEATTLE, April 10, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, issued draft guidance on PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL). The draft guidance does...

SEATTLE, Sept. 11, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri® in the European Union ("E.U.") with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012. CTI plans to expand availability to...

A University of Rochester Medical Center study challenges treatment guidelines for early stage follicular lymphoma, concluding that six different therapies can bring a remission, particularly if the patient is carefully examined and staged at diagnosis. The research underlines the fact that when cancer strikes, modern patients and their oncologists across the United States are taking many diverse treatment paths when there is scant data to support one method over another. This study...

SEATTLE, May 31, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that results from its PIX301 phase 3 clinical trial of Pixuvri® (pixantrone) have been published online in The Lancet Oncology. The publication authored by Ruth Pettengell, M.D., et al, is titled "Phase 3 Trial Comparing Pixantrone Dimaleate with other Chemotherapeutic Agents as a Single-agent, Salvage Treatment in Patients with Relapsed or Refractory Aggressive non-Hodgkin...

SEATTLE, May 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that it has received conditional marketing authorization from the European Commission ("EC") for Pixuvri® (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas ("NHL"). Pixuvri is the first approved treatment in the European Union ("EU") in this patient setting. (Photo:...

MOUNTAIN VIEW, Calif., March 20, 2012 /PRNewswire/ -- SanBio Inc. today announced the successful enrollment of the first dose cohort of patients in its Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic stem cell therapy product, SB623, in patients suffering from chronic deficits resulting from previous stroke injuries. The first 6 patients, of a total of 18, have been successfully administered SB623. The trial is being conducted at Stanford University...

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has reached the target enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) for a Special Protocol Assessment (SPA) and has...